Granulomatosis with Polyangiitis Clinical Trials

Find Granulomatosis with Polyangiitis Clinical Trials Near You

Benralizumab Effectiveness in the LONG-term Real-life Setting in EGPA: The BELONG-EGPA Study

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY

This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting. The study will include patients treated with benralizumab 30 mg every 4 weeks at EGPA referral centers participating in the European EGPA Study Group. Clinical, laboratory, lung function, treatment, relapse, and safety data will be collected from medical charts at baseline and during follow-up up to 24 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or older.

• Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) according to the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria or the criteria proposed in the MIRRA trial.

• Treatment with benralizumab 30 mg every 4 weeks.

• At least 3 months of available follow-up data after starting benralizumab.

• Written informed consent for study participation and data collection.

Locations
Other Locations
Italy
Edoardo Biancalana
RECRUITING
Florence
Contact Information
Primary
Giacomo Emmi, MD/PhD
giacomo.emmi0105@gmail.com
+393286852815
Backup
Irene Mattioli, PharmD/PhD
irene.mattioli@unifi.it
Time Frame
Start Date: 2026-02-11
Estimated Completion Date: 2028-02-11
Participants
Target number of participants: 100
Treatments
Patients with EGPA treated with benralizumab
Adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) receiving benralizumab 30 mg every 4 weeks in a real-world setting. Patients may be newly diagnosed or have relapsing or refractory EGPA and must have at least 3 months of available follow-up after starting benralizumab.
Sponsors
Leads: European EGPA Study Group

This content was sourced from clinicaltrials.gov